Dyadic International Inc (DYAI)

NASDAQ
Currency in USD
0.996
-0.054(-5.14%)
Closed·
After Hours
0.990-0.006(-0.602%)
·
DYAI Scorecard
Full Analysis
Stock has fared poorly over the last month
DYAI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.9801.050
52 wk Range
0.9262.670
Key Statistics
Edit
Prev. Close
1.05
Open
1.04
Day's Range
0.98-1.05
52 wk Range
0.926-2.67
Volume
26.17K
Average Volume (3m)
41.62K
1-Year Change
-48.92%
Book Value / Share
0.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DYAI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations
Show more

Dyadic Company Profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa’s Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Dyadic International Inc Earnings Call Summary for Q1/2025

  • Q1 2025: EPS -$0.07 met expectations, revenue $393,570 slightly missed forecast; stock rose 3.85% in aftermarket trading
  • Strategic shift: Focus on non-pharma products, including recombinant human serum albumin launch in Q3 2025 and dairy enzymes by year-end
  • Reduced paid collaborators from 9 to 4; pivoting to product-driven revenue-generating enterprise from development-stage biotech
  • Cash and securities at $7.4M as of March 31, 2025; exploring revenue opportunities through partnerships with FirmBox and ProLiant
  • CEO: Q1 marks pivotal step in evolution; COO: Reprioritizing resources for non-pharmaceutical sector revenue generation
Last Updated: 14/05/2025, 22:46
Read Full Transcript

Compare DYAI to Peers and Sector

Metrics to compare
DYAI
Peers
Sector
Relationship
P/E Ratio
−5.1x−0.5x−0.4x
PEG Ratio
−0.190.000.00
Price/Book
32.4x0.7x2.6x
Price / LTM Sales
8.4x23.3x2.9x
Upside (Analyst Target)
-296.0%54.4%
Fair Value Upside
Unlock22.3%9.3%Unlock

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.07 / --
Revenue / Forecast
393.57K / --
EPS Revisions
Last 90 days

People Also Watch

30.39
SMTI
-1.94%
0.8200
BBLG
-2.38%
1.030
ALLR
-3.29%
0.0725
ONCO
-14.00%

FAQ

What Is the Dyadic (DYAI) Stock Price Today?

The Dyadic stock price today is 1.00

What Stock Exchange Does Dyadic Trade On?

Dyadic is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Dyadic?

The stock symbol for Dyadic is "DYAI."

What Is the Dyadic Market Cap?

As of today, Dyadic market cap is 29.96M.

What Is Dyadic's Earnings Per Share (TTM)?

The Dyadic EPS (TTM) is -0.20.

When Is the Next Dyadic Earnings Date?

Dyadic will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is DYAI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Dyadic Stock Split?

Dyadic has split 0 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.